Watch the webcasts from our industry partners Satellite Symposia
BREAST CANCER
Advancing Knowledge in Early and Metastatic Triple-Negative Breast Cancer
F. Hoffmann-La Roche
-
The biology of breast cancer: Lessons from the past
Sandra Swain, Washington, United States -
Raising the bar in early TNBC
Peter Schmid, London, United Kingdom -
Insights from the clinic: Hypothetical eTNBC Patient Scenario(s)
Carlos Barrios, Porto Alegre, Brazil -
New frontiers in metastatic TNBC
Rebecca Dent, Singapore, Singapore -
Insights from the clinic: Hypothetical mTNBC Patient Scenario(s)
Carlos Barrios, Porto Alegre, Brazil -
Looking at the future horizon
Sandra Swain, Washington, United States -
Live Q&A
Sandra Swain, Washington, United States, Peter Schmid, London, United Kingdom, Carlos Barrios, Porto Alegre, Brazil, Rebecca Dent, Singapore, Singapore
HER tomorrow in HER2+ metastatic breast cancer
AstraZeneca
-
Welcome and introductions
Eva Ciruelos, Madrid, Spain -
HER past: Looking back on two decades of HER2-targeted therapy
Eva Ciruelos, Madrid, Spain, Fatima Cardoso, Lisbon, Portugal -
HER new potential: New advances in HER2+ breast cancer treatment
Erika Hamilton, Nashville, United States -
Sharing HER experience: Case-based panel discussion
Eva Ciruelos, Madrid, Spain, Erika Hamilton, Nashville, United States, Karen Gelmon, Vancouver, Canada, Fatima Cardoso, Lisbon, Portugal -
Closing remarks
Eva Ciruelos, Madrid, Spain
The complete picture: Managing breast cancer in the real-world
Pfizer Oncology
-
Setting the scene: The evolution of breast cancer care
Antonio Llombart Cussac, Lleida, Spain -
Framing the shot: Examining current practice in HR+/HER2- aBC
Adam Brufsky, Pittsburgh, United States -
Changing perspectives: Exploring the patient focus in HR+/HER2- aBC
Adam Brufsky, Pittsburgh, United States -
Views from the clinic: Challenges, choices, and confidence when treating your patients with germline BRCA-mutated HER2- LA or mBC
Suzette Delaloge, Paris, France -
New perspectives: Looking to the future of breast cancer care
Antonio Llombart Cussac, Lleida, Spain -
Live Q&A
Antonio Llombart Cussac, Lleida, Spain
Transforming patient care: Leveraging the latest clinical data in HER2-positive eBC
F. Hoffmann-La Roche
-
Welcome and Introduction: Evolution of patient care in HER2-positive eBC
Eva Ciruelos, Madrid, Spain -
How to ensure optimal treatment for patients with residual disease
Andrew Wardley, Manchester, United Kingdom -
Continuing a patient's journey after pCR: Evidence-based decision–making
Christian Jackisch, Offenbach am Main, Germany -
Panel discussion
Eva Ciruelos, Madrid, Spain, Christian Jackisch, Offenbach am Main, Germany, Andrew Wardley, Manchester, United Kingdom -
Summary and close
Eva Ciruelos, Madrid, Spain -
Live Q&A
Eva Ciruelos, Madrid, Spain
GASTROINTESTINAL TUMOURS
Can current treatment strategies for mCRC be further optimized?
Servier
-
Introduction
Fortunato Ciardiello, Napoli, Italy -
Optimizing treatment strategies in the first-line mCRC
Thierry André, Paris, France, Mark Saunders, Manchester, United Kingdom -
Extending the continuum of care beyond the second-line mCRC
Per Pfeiffer, Odense, Denmark, Timothy Price, Woodville, Australia -
Conclusion
Fortunato Ciardiello, Napoli, Italy -
Live Q&A
Fortunato Ciardiello, Napoli, Italy
Current status and future directions for immunotherapy in hepatocellular carcinoma
AstraZeneca
-
Current status and future directions for immunotherapy in hepatocellular carcinoma
Ghassan Abou-Alfa, New York, United States, Bruno Sangro, Pamplona, Spain, Peter R. Galle, Mainz, Germany
Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
F. Hoffmann-La Roche
-
Welcome and introductions
Arndt Vogel, Hannover, Germany -
Tracking the recent advances within the field of unresectable HCC
David Pinato, London, United Kingdom -
Reviewing the latest phase III efficacy data for unresectable HCC
Andrew Zhu, Boston, United States -
Exploring key safety data for cancer immunotherapy combinations
Philippe Merle, Lyon, France -
Moving into the clinic: how will these data inform our clinical decisions?
Arndt Vogel, Hannover, Germany -
Panel discussion
Arndt Vogel, Hannover, Germany, David Pinato, London, United Kingdom, Philippe Merle, Lyon, France, Andrew Zhu, Boston, United States -
Live Q&A
Arndt Vogel, Hannover, Germany
Joining efforts beyond first-line management in patients with metastatic pancreatic cancer
Servier
-
Welcome and introduction
Gerald Prager, Vienna, Austria -
Tumor Registry Pancreatic Cancer: A national registry for the evaluation of treatment strategies in pancreatic cancer
Norbert Marschner, Freiburg im Breisgau, Germany -
Joining efforts across the borders in improving mPDAC patient outcomes
Gerald Prager, Vienna, Austria, Junji Furuse, Tokyo, Japan -
Exploring new treatment strategies to improve outcomes for patients with metastatic pancreatic cancer
Cindy Neuzillet, Clichy, France -
Conclusion
Gerald Prager, Vienna, Austria -
Live Q&A
Gerald Prager, Vienna, Austria
The future is now: Transforming management of GI cancer with immuno-oncology
Bristol Myers Squibb
-
The future is now: Transforming management of GI cancer with immuno-oncology
Markus Möhler, Mainz, Germany, Sara Lonardi, Padova, Italy, Elizabeth Smyth, Cambridge, United Kingdom
The today and tomorrow of systemic treatment for HCC
Ipsen
-
Welcome and introductions
Peter R. Galle, Mainz, Germany -
Understanding the current landscape: Insights from clinical practice
Thomas Yau, Hong Kong, China -
How data could shape the future of clinical practice
Lorenza Rimassa, Rozzano, Italy -
Close
Peter R. Galle, Mainz, Germany -
Live Q&A
Peter R. Galle, Mainz, Germany, Thomas Yau, Hong Kong, China, Lorenza Rimassa, Rozzano, Italy
GENITOURINARY TUMOURS (NON-PROSTATE)
Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach in aRcc
Bristol Myers Squibb
-
Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach
James Larkin, London, United Kingdom, Nizar Tannir, Houston, United States, Michael Atkins, Washington DC, United States
Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
F. Hoffmann-La Roche
-
Welcome and introduction
Karim Fizazi, Villejuif, France -
Improving outcomes with immunotherapy in urothelial cancer: Perspectives on the latest data
Enrique Grande, Madrid, Spain -
The changing landscape of metastatic prostate cancer: Challenges and evolving opportunities
Karim Fizazi, Villejuif, France -
Targeting AKT: Next breaAKThrough therapies for prostate cancer care?
Johann de Bono, London, United Kingdom -
Live Q&A
Karim Fizazi, Villejuif, France
What does the changing treatment landscape for aRCC mean for patient care: An expert discussion
Ipsen
-
Welcome and introduction
Cristina Suarez, Barcelona, Spain -
Shifting perceptions in the first-line treatment of aRCC
Toni Choueiri, Boston, United States - Personalizing treatment approaches in clinical practice. Part 1: Sequencing of treatment in aRCC following progression
Camillo Guglielmo Porta, Pavia, Italy - Personalizing treatment approaches in clinical practice. Part 2: Understanding the patient experience of aRCC
Howard Gurney, Sydney, Australia -
Closing comments
Cristina Suarez, Barcelona, Spain -
Live Q&A
Cristina Suarez, Barcelona, Spain
GENITOURINARY TUMOURS (PROSTATE)
Advanced prostate cancer: How do we move forward in patient management?
Janssen
-
Optimising care for individual patients with metastatic hormone sensitive prostate cancer
Eleni Efstathiou, Houston, United States, Elena Castro, Madrid, Spain, Nicolas Mottet, Saint-Etienne, France, Kim Chi, Vancouver, Canada, Boris Hadaschik, Essen, Germany -
Non metastatic castration resistant prostate cancer translating benefit to clinical practice & Choosing the right pathway in the current and future management of metastatic castration resistant prostate cancer
Boris Hadaschik, Essen, Germany, Kim Chi, Vancouver, Canada, Elena Castro, Madrid, Spain, Eleni Efstathiou, Houston, United States, Nicolas Mottet, Saint-Etienne, France -
Flattening the curve: Consequences for the management of prostate cancer in the ongoing COVID-19 pandemic
Eleni Efstathiou, Houston, United States, Boris Hadaschik, Essen, Germany, Nicolas Mottet, Saint-Etienne, France, Kim Chi, Vancouver, Canada, Elena Castro, Madrid, Spain -
Live Q&A
Eleni Efstathiou, Houston, United States, Nicolas Mottet, Saint-Etienne, France, Boris Hadaschik, Essen, Germany, Elena Castro, Madrid, Spain, Kim Chi, Vancouver, Canada
Building a new paradigm in prostate cancer
Pfizer Oncology
-
Challenges in the treatment of prostate cancer
Daniel George, Durham, United States -
Maximizing outcome with NHTs
Arnulf Stenzl, Tuebingen, Germany -
Expanding the potential of PARP inhibitors
Joaquin Mateo, Barcelona, Spain -
Summary
Daniel George, Durham, United States -
Live Q&A
Daniel George, Durham, United States, Joaquin Mateo, Barcelona, Spain, Arnulf Stenzl, Tuebingen, Germany
Extending overall survival in nmCRPC while maintaining quality of life: Can we have it all?
PeerVoice
-
Welcome and introduction
Neal Shore, Myrtle Beach, United States -
Overall Survival in nmCRPC: Translating Recent Data Into a Plan of Action
Neal Shore, Myrtle Beach, United States, Karim Fizazi, Villejuif, France, Gero Kramer, Vienna, Austria, Jennifer Sutton, Myrtle Beach, United States -
Mitigating and managing adverse events associated with androgen receptor-targeted therapies
Neal Shore, Myrtle Beach, United States, Jennifer Sutton, Myrtle Beach, United States, Karim Fizazi, Villejuif, France, Gero Kramer, Vienna, Austria -
Quality of life as a therapeutic goal for nmCRPC
Neal Shore, Myrtle Beach, United States, Karim Fizazi, Villejuif, France, Jennifer Sutton, Myrtle Beach, United States, Gero Kramer, Vienna, Austria -
Case studies in nmCRPC: Applying knowledge to practice
Neal Shore, Myrtle Beach, United States, Gero Kramer, Vienna, Austria, Jennifer Sutton, Myrtle Beach, United States, Karim Fizazi, Villejuif, France -
Faculty Q&A and Take-Home Messages
Neal Shore, Myrtle Beach, United States, Karim Fizazi, Villejuif, France, Gero Kramer, Vienna, Austria, Jennifer Sutton, Myrtle Beach, United States
PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
AstraZeneca
-
Chair’s welcome and introductions
Neal Shore, Myrtle Beach, United States -
Exploring molecular heterogeneity in prostate cancer - prevalence and clinical significance
Neal Shore, Myrtle Beach, United States -
Dissecting the clinical data for PARP inhibitors in metastatic castrate resistant prostate cancer
Joaquin Mateo, Barcelona, Spain -
Considerations for the approach to HRRm testing in prostate cancer
Alexander Wyatt, Vancouver, Canada -
Panel discussion
Neal Shore, Myrtle Beach, United States, Joaquin Mateo, Barcelona, Spain, Alexander Wyatt, Vancouver, Canada -
Summary and meeting close
Neal Shore, Myrtle Beach, United States
Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
F. Hoffmann-La Roche
-
Welcome and introduction
Karim Fizazi, Villejuif, France -
Improving outcomes with immunotherapy in urothelial cancer: Perspectives on the latest data
Enrique Grande, Madrid, Spain -
The changing landscape of metastatic prostate cancer: Challenges and evolving opportunities
Karim Fizazi, Villejuif, France -
Targeting AKT: Next breaAKThrough therapies for prostate cancer care?
Johann de Bono, London, United Kingdom
GYNECOLOGICAL TUMOURS
Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
AstraZeneca
-
Chair’s welcome and introductions
Ana Oaknin, Barcelona, Spain -
Pioneering with PARP inhibition: rationale for maintenance therapy in newly diagnosed ovarian cancer
Thomas Herzog, Cincinnati, United States - Broadening horizons: new data and combinations with PARP inhibitors
Isabelle Ray-Coquard, Lyon, France -
Optimising clinical outcomes: the case for personalised medicine in ovarian cancer
Ignace Vergote, Leuven, Belgium -
Panel discussion
Ana Oaknin, Barcelona, Spain, Isabelle Ray-Coquard, Lyon, France, Thomas Herzog, Cincinnati, United States, Ignace Vergote, Leuven, Belgium -
Summary and meeting close
Ana Oaknin, Barcelona, Spain
Update on the evolving landscape for endometrial cancer treatment with Immunotherapy
GSK
-
Welcome and Introduction
Robert Coleman, The Woodlands, United States, Robert Coleman, The Woodlands, United States -
Evolution of diagnosis and classification of endometrial cancer and emergence of molecular classification
Amit Oza, Toronto, Canada -
Endometrial cancer as an attractive target for checkpoint inhibitor-based therapy
Robert Coleman, The Woodlands, United States -
Monotherapy checkpoint inhibitor studies in recurrent endometrial cancer
Renaud Sabatier, Marseille, Cedex 09, France -
Combination checkpoint inhibitor studies in newly diagnosed and recurrent endometrial cancer
Ana Oaknin, Barcelona, Spain -
Patient journeys of 2 women with recurrent/advanced EC
Ana Oaknin, Barcelona, Spain, Robert Coleman, The Woodlands, United States -
Conclusion
Ana Oaknin, Barcelona, Spain, Robert Coleman, The Woodlands, United States -
Live Q&A
Ana Oaknin, Barcelona, Spain, Robert Coleman, The Woodlands, United States
IMMUNO-ONCOLOGY
Antibody Drug Conjugates (ADCs): Advancements in the treatment of solid tumours
Daiichi Sankyo
-
Welcome and introduction
Pasi Jänne, Boston, United States -
ADCs as a technologically advanced treatment approach in solid tumours
Pasi Jänne, Boston, United States -
Current clinical experience with innovative ADCs in breast cancer
Javier Cortés, Barcelona, Spain -
Latest findings from clinical trials in lung cancer with technologically advanced ADCs
Pasi Jänne, Boston, United States -
Recent clinical findings with novel ADCs in colorectal and gastric cancer
Kanwal Raghav, Houston, United States -
Summary and close
Pasi Jänne, Boston, United States -
Live Q&A
Pasi Jänne, Boston, United States
Current status and future directions for immunotherapy in hepatocellular carcinoma
AstraZeneca
-
Current status and future directions for immunotherapy in hepatocellular carcinoma
Ghassan Abou-Alfa, New York, United States, Bruno Sangro, Pamplona, Spain, Peter R. Galle, Mainz, German
Exploring the Current and Evolving Landscape in Thoracic Cancers
Bristol Myers Squibb
-
Exploring the current and evolving landscape in thoracic cancers
Martin Reck, Grosshansdorf, Germany, Paul Baas, Amsterdam, Netherlands, Tina Cascone, Houston, United States -
Live Q&A
Martin Reck, Grosshansdorf, Germany, Tina Cascone, Houston, United States, Paul Baas, Amsterdam, Netherlands
Immune checkpoint blockade in non-melanoma skin cancer
Sanofi Genzyme
-
Welcome introduction and objectives and Treatment for locally advanced/metastatic cutaneous squamous cell carcinoma (CSCC)
Chrysalyne Schmults, Harvard, United States -
Exploring the emerging research with immuno-oncology in CSCC
Dirk Schadendorf, Essen, Germany -
Emerging research with immune checkpoint inhibitors in basal cell carcinoma (BCC)
Susana Puig, Barcelona, Spain
Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
F. Hoffmann-La Roche
-
Welcome and introductions
Arndt Vogel, Hannover, Germany -
Tracking the recent advances within the field of unresectable HCC
David Pinato, London, United Kingdom -
Reviewing the latest phase III efficacy data for unresectable HCC
Andrew Zhu, Boston, United States -
Exploring key safety data for cancer immunotherapy combinations
Philippe Merle, Lyon, France -
Moving into the clinic: how will these data inform our clinical decisions?
Arndt Vogel, Hannover, Germany -
Panel discussion
Arndt Vogel, Hannover, Germany, David Pinato, London, United Kingdom, Philippe Merle, Lyon, France, Andrew Zhu, Boston, United States -
Live Q&A
Arndt Vogel, Hannover, Germany
Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
F. Hoffmann-La Roche
-
Welcome and introduction
Karim Fizazi, Villejuif, France -
Improving outcomes with immunotherapy in urothelial cancer: Perspectives on the latest data
Enrique Grande, Madrid, Spain -
The changing landscape of metastatic prostate cancer: Challenges and evolving opportunities
Karim Fizazi, Villejuif, France -
Targeting AKT: Next breaAKThrough therapies for prostate cancer care?
Johann de Bono, London, United Kingdom -
Live Q&A
Karim Fizazi, Villejuif, France
The future is now: Transforming management of GI cancer with immuno-oncology
Bristol Myers Squibb
-
The future is now: Transforming management of GI cancer with immuno-oncology
Markus Möhler, Mainz, Germany, Sara Lonardi, Padova, Italy, Elizabeth Smyth, Cambridge, United Kingdom
Update on the evolving landscape for endometrial cancer treatment with Immunotherapy
GSK
-
Welcome and Introduction
Robert Coleman, The Woodlands, United States, Robert Coleman, The Woodlands, United States -
Evolution of diagnosis and classification of endometrial cancer and emergence of molecular classification
Amit Oza, Toronto, Canada -
Endometrial cancer as an attractive target for checkpoint inhibitor-based therapy
Robert Coleman, The Woodlands, United States -
Monotherapy checkpoint inhibitor studies in recurrent endometrial cancer
Renaud Sabatier, Marseille, Cedex 09, France -
Combination checkpoint inhibitor studies in newly diagnosed and recurrent endometrial cancer
Ana Oaknin, Barcelona, Spain -
Patient journeys of 2 women with recurrent/advanced EC
Ana Oaknin, Barcelona, Spain, Robert Coleman, The Woodlands, United States -
Conclusion
Ana Oaknin, Barcelona, Spain, Robert Coleman, The Woodlands, United States -
Live Q&A
Ana Oaknin, Barcelona, Spain, Robert Coleman, The Woodlands, United States
LUNG CANCER
Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon
Janssen
-
An overview of NSCLC
Pilar Garrido, Madrid, Spain, Marina Garassino, Milan, Italy -
Uncommon EGFR mutations in NSCLC
Matthew Krebs, Manchester, United Kingdom, Zosia Piotrowska, Boston, United States -
Looking to the future: How can emerging therapeutic options influence the management landscape
Lecia Sequist, Boston, United States, Benjamin Besse, Villejuif, France -
Live Q&A
Pilar Garrido, Madrid, Spain, Matthew Krebs, Manchester, United Kingdom, Lecia Sequist, Boston, United States
Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Pfizer Oncology
-
Welcome and introduction
Rosario Garcia Campelo, A Coruña, Spain -
Latest updates in molecular testing in NSCLC
Justin Gainor, Boston, United States -
EGFR+ NSCLC: A personalised sequencing approach
Jesus Corral Jaime, Pamplona, Spain -
ALK+ and ROS1+ NSCLC: Optimising patient outcomes
Todd Bauer, Nashville, United States
Treatment Options for Non-Small Cell Lung Cancer
Boehringer Ingelheim
-
Welcome and introduction
Tanja Čufer, Golnik, Slovenia -
Treatments After Progression in the First-Line of Non-Mutated NSCLC Adenocarcinoma
Silvia Novello, Turin, Italy -
Uncommon EGFR Mutations
Xiuning Le, Houston, United States -
The Future of NSCLC
Melissa Johnson, Nashville, United States -
Key insights and closing remarks
Tanja Čufer, Golnik, Slovenia -
Live Q&A
Tanjia Čufer, Golnik, Slovenia, Xiuning Le, Houston, United States, Melissa Johnson, Nashville, United States, Silvia Novello, Turin, Italy
Evolving strategies: Managing treatment of early stage and advanced lung cancers
AstraZeneca
-
Welcome and Introduction
David Spigel, Nashville, United States -
Extensive-stage SCLC: Changing the paradigm with immune-oncology combinations
David Spigel, Nashville, United States -
Unresectable stage III NSCLC: Clinical advances in the implementation of immuno-oncology therapy
Johan Vansteenkiste, Leuven, Belgium -
Early stage EGFRm NSCLC: Targeted treatment options following complete surgical resection
Tom John, Heidelberg, Australia -
Locally advanced or metastatic EGFRm NSCLC: Targeted treatment options to improve outcomes in the first-line setting and beyond progression
David Planchard, Villejuif, France
Exploring the Current and Evolving Landscape in Thoracic Cancers
Bristol Myers Squibb
-
Exploring the current and evolving landscape in thoracic cancers
Martin Reck, Grosshansdorf, Germany, Paul Baas, Amsterdam, Netherlands, Tina Cascone, Houston, United States -
Live Q&A
Martin Reck, Grosshansdorf, Germany, Tina Cascone, Houston, United States, Paul Baas, Amsterdam, Netherland
MELANOMA AND OTHER SKIN CANCERS
Immune checkpoint blockade in non-melanoma skin cancer
Sanofi Genzyme
-
Welcome introduction and objectives and Treatment for locally advanced/metastatic cutaneous squamous cell carcinoma (CSCC)
Chrysalyne Schmults, Harvard, United States -
Exploring the emerging research with immuno-oncology in CSCC
Dirk Schadendorf, Essen, Germany -
Emerging research with immune checkpoint inhibitors in basal cell carcinoma (BCC)
Susana Puig, Barcelona, Spain
Melanoma in 2020: Reflect, reset, and continue
Bristol Myers Squibb
-
Melanoma in 2020: Reflect, reset, and continue
James Larkin, London, United Kingdom, Pippa Corrie, Cambridge, United Kingdom, Paolo Ascierto, Naples, Italy
PRECISION MEDICINE
NGS Biomarker testing: Time matters . No longer need to wait for weeks, as this can now happen within days
Thermo Fisher Scientific
-
Introduction
L. Quagliata (Basel, Switzerland) -
Genomic profiling is driving the precision oncology
P. Jermann (Basel, Switzerland) -
Lung cancer diagnostic test needs: perspective from a thoracic oncologist
G. Fernandes (Porto, Portugal) -
Establishment of a large-scale Asian genomic screening platform to identify non-small cell lung cancer with rare driver oncogenes and clarify drug resistant mechanisms
K. Goto (Kashiwa, Japan) -
NTRK, RET and other fusion biomarkers testing: Latest developments
P. Jermann (Basel, Switzerland)
Precision medicine in Real-world clinical practice: Perspectives from a multidisciplinary team
Bayer
-
Precision medicine in Real-world clinical practice: Perspectives from a multidisciplinary team
Jean-Yves Blay, Lyon, France, Jesus Garciafoncillas, Madrid, Spain, Gilad Vainer, Jerusalem, Israel, Maximilian Hochmair, Vienna, Austria, Marcia Simpson Brose,Philadelphia, United States
Putting personalised healthcare at the heart of clinical practice
F. Hoffmann-La Roche
-
Taking the pulse of personalised healthcare today
Emile Voest, Amsterdam, Netherlands -
Tracing our path with current tools
Shumei Kato, San Diego, United States -
If tissue is the issue, think blood
Natalie Cook, Manchester, United Kingdom -
Learning from real-world patients, in real-life conditions
Kenneth Kehl, Boston, United States -
Looking at where personalised healthcare has become reality
Emile Voest, Amsterdam, Netherlands -
Conclusion
Emile Voest, Amsterdam, Netherlands -
Live Q&A
Emile Voest, Amsterdam, Netherlands
REAL WORLD EVIDENCE / MULTIDISCIPLINARY
Precision medicine in Real-world clinical practice: Perspectives from a multidisciplinary team
Bayer
-
Precision medicine in Real-world clinical practice: Perspectives from a multidisciplinary team
Jean-Yves Blay, Lyon, France, Jesus Garciafoncillas, Madrid, Spain, Gilad Vainer, Jerusalem, Israel, Maximilian Hochmair, Vienna, Austria, Marcia Simpson Brose,Philadelphia, United States
RWE and me: Multidisciplinary views on real-world evidence (RWE) in oncology
Pfizer Oncology
-
Welcome and introduction
George Demetri, Boston, United States -
The patient perspective: The relevance of RWE in patient decision-making
Renate Haidinger, Hohenbrunn, Germany -
The physician perspective: Using RWE to inform clinical decisions in day-to-day practice and drug discovery
George Demetri, Boston, United States -
The regulator perspective: RWE and real-world data (RWD) in drug approvals and label expansions
Jorge Camarero, Madrid, Spain -
The payer perspective: Utilising RWD to determine the value of drugs
Oriol Solà-Morales, Sant Cugat del Valles, Spain -
Panel discussion
George Demetri, Boston, United States, Jorge Camarero, Madrid, Spain, Oriol Solà-Morales, Sant Cugat del Valles, Spain, Renate Haidinger, Hohenbrunn, Germany -
Live Q&A
George Demetri, Boston, United States
The complete picture: Managing breast cancer in the real-world
Pfizer Oncology
-
Setting the scene: The evolution of breast cancer care
Antonio Llombart Cussac, Lleida, Spain -
Framing the shot: Examining current practice in HR+/HER2- aBC
Adam Brufsky, Pittsburgh, United States -
Changing perspectives: Exploring the patient focus in HR+/HER2- aBC
Adam Brufsky, Pittsburgh, United States -
Views from the clinic: Challenges, choices, and confidence when treating your patients with germline BRCA-mutated HER2- LA or mBC
Suzette Delaloge, Paris, France -
New perspectives: Looking to the future of breast cancer care
Antonio Llombart Cussac, Lleida, Spain -
Live Q&A
Antonio Llombart Cussac, Lleida, Spain